MedTrace Logo

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

NCT00290485 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2006-04-07

No results posted yet for this study

Summary

The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.

Conditions

Interventions

DRUG

Imatinib mesylate

Sponsors & Collaborators

  • Hippocrate Research & Development

    collaborator UNKNOWN

  • Maisonneuve-Rosemont Hospital

    lead OTHER

Principal Investigators

  • Pierre Dubé, MD · Maisonneuve-Rosemont Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290485 on ClinicalTrials.gov